Personalised medicine is revolutionising healthcare by adapting treatments to each individual's unique genetic makeup, lifestyle, and environmental factors. This approach offers more effective care with fewer side effects, moving away from the traditional 'one-size-fits-all' model.
Key Examples of Personalised Medicine in Action
- Cancer Care Customisation: Personalised medicine enables oncologists to target specific mutations in a patient’s cancer, improving treatment effectiveness and minimising damage to healthy cells. Targeted therapies have shown to significantly increase survival rates (Schilsky, 2020).
- Tailored Immunotherapy for Cancer: Personalised immunotherapies modify the body’s immune response to better target cancer, substantially improving outcomes compared to conventional treatments (Postow et al., 2018).
- Gene Therapy Advances: For genetic disorders like cystic fibrosis and sickle cell disease, gene therapy introduces correct genes to replace faulty ones, offering life-changing improvements and potential cures (Nienhuis et al., 2017).
- Diabetes Treatment Personalisation: Diabetes treatments can be tailored based on an individual's genetic markers, enhancing blood sugar management and overall quality of life (American Diabetes Association, 2019).
- Mental Health Treatments: By understanding genetic variations that affect drug response, personalised medicine allows for more accurate medication prescriptions in mental health, reducing trial and error (Bousman & Hopwood, 2016).
- Heart Disease Prevention: Genetic screening helps identify individuals at increased risk of heart disease, enabling customised preventative measures that can significantly reduce heart attack and stroke risks (Khera & Kathiresan, 2017).
- Optimising Sleep: Analysing genetic factors can lead to personalised sleep hygiene recommendations, improving sleep quality for those with specific predispositions (Besedovsky et al., 2019).
- Nutritional Planning: Personalised diets, tailored to genetic predispositions, can significantly decrease risks for diseases like obesity and diabetes, promoting better health (Ordovas et al., 2018).
- The Role of AI in Personalised Medicine: AI and machine learning enhance personalised medicine by predicting individual responses to treatments, leading to more effective healthcare strategies (Jiang et al., 2017).
Personalised medicine is actively transforming healthcare, driven by significant advancements in cell therapy, gene therapy, and tissue engineering. These fields are at the forefront of medical innovation, providing targeted and efficient treatments that were once deemed impossible. However, the progress and realisation of their full potential relies on sustained R&D investments. Collaborating with the right partners is crucial for pharma and biotech companies to navigate this complex landscape, accelerating research, and bringing ground-breaking therapies to market. As this sector continues to evolve, strategic partnerships and investments will undoubtedly play a pivotal role in shaping a future where healthcare is customised to meet the unique needs of every individual, ensuring better outcomes for all.
At
Biopharma Group
, we help companies of all sizes develop their drug products and we do it quickly.
- Schilsky, R. L. (2020). Personalised Medicine in Oncology: The Future is Now.
- Nienhuis, A. W., et al. (2017). Gene Therapy for Hemophilia.
- American Diabetes Association (2019). Pharmacologic Approaches to Glycaemic Treatment.
- Postow, M. A., et al. (2018). Immune Checkpoint Blockade in Cancer Therapy.
- Bousman, C. A., & Hopwood, M. (2016). Commercial Pharmacogenetics and Personalised Medicine Decision Support.
- Khera, A. V., & Kathiresan, S. (2017). Genetics of Coronary Artery Disease.
- Besedovsky, L., et al. (2019). The Sleep-Immune Crosstalk in Health and Disease.
- Ordovas, J. M., et al. (2018). Personalised Nutrition and Cardiovascular Disease Prevention.
- Jiang, F., et al. (2017). Artificial Intelligence in Healthcare: Past, Present and Future.
This LinkedIn article, authored by Dr Mattia Cassanelli, Joint Head of Sales - Pharma R&D, part of the CDMO business development division at Biopharma Group.
Lyoprotect? - the key to safe lyophilization
6 个月Dear Mattia, Thank you for this post - remarkably interesting! I am wondering and would like to have your opinion. Do you have an idea how many of the above-mentioned personalized medicine would need improved shelf life? Is it worth to develop a formulation suitable for lyophilization – or is it in principal better for proteins to be stabilized by cryo-protectants and lyophilization??